Login / Signup

Hydroxyurea use in young infants with sickle cell disease.

Sarah B SchuchardJennifer R LissickAmanda NickelDavid WatsonKristin L MoquistRae M BlaylarkStephen C Nelson
Published in: Pediatric blood & cancer (2019)
HU is safe and effective in patients 5 to 12 months of age and generated a more robust response compared with initiation in older patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • sickle cell disease